This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genzyme’s Multiple Sclerosis Franchise Featured At AAN

Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today that data from its AUBAGIO ® (teriflunomide) and LEMTRADA TM (alemtuzumab) multiple sclerosis clinical development programs will be presented during the 65 th American Academy of Neurology (AAN) Annual Meeting to be held in San Diego, Calif., March 16-23.

We are proud to present these results that offer important new insights into AUBAGIO and LEMTRADA,” said Genzyme CEO and President, David Meeker, MD. “ Our robust clinical development programs underscore our steadfast commitment to advancing our understanding of multiple sclerosis and its treatment, and to providing new hope for people living with this devastating disease.

Data from across the company’s clinical development programs to be presented at AAN during Pacific Time are as follows, along with details about the Genzyme Corporate Therapeutic Update and Brain Health Fair sponsorship.

Platform Presentations for AUBAGIO and LEMTRADA:

AUBAGIO:
  • Pre-Defined Subgroups Analyses of TOWER, a Placebo‐Controlled Phase 3 Trial of Teriflunomide in Patients with Relapsing Multiple Sclerosis (Platform Presentation Session 41 – S41.006; March 21; 1:30 p.m.)
  • Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results From TOWER, a Second, Pivotal, Phase 3 Placebo‐Controlled Study (Platform Presentation Session 1 – S01.004; March 19; 1:45 p.m.)
  • Pregnancy Outcomes From the Teriflunomide Clinical Development Program: Retrospective Analysis of the Teriflunomide Clinical Trial Database (Platform Presentation Session 30 – S30.005; March 20; 3:00 p.m.)

LEMTRADA:
  • Durable Efficacy of Alemtuzumab in Relapsing‐Remitting Multiple Sclerosis Patients Who Participated in the CARE‐MS Studies: Three Year Follow‐Up (Platform Presentation Session 41 – S41.001; March 21; 12:00 p.m.)

Additional Presentations:

AUBAGIO:

Poster Presentations
  • Immune Response to Seasonal Influenza Vaccination in Patients with Relapsing Multiple Sclerosis Treated with Teriflunomide: the TERIVA Study (Poster Session I – P01.169; March 18; 2:00 p.m.)
  • Frequency of Infections During Treatment with Teriflunomide: Pooled Data From Three Placebo‐Controlled Teriflunomide Studies (Poster Session I – P01.171; March 18; 2:00 p.m.)
  • Teriflunomide Reduces Relapse‐Related Sequelae, Hospitalizations and Corticosteroid Use: A Post‐Hoc Analysis of the Phase 3 TOWER Study (Poster Session VII – P07.109; March 21; 2:00 p.m.)

LEMTRADA:

Poster Presentations
  • Disability Improvement with Alemtuzumab vs. Interferon beta‐1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE‐MS II) (Poster Session VII – P07.120; March 21; 2:00 p.m.)
  • Efficacy of Alemtuzumab vs IFNB‐1a in Relapsing‐Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE‐MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (Poster Session VII – P07.111; March 21; 2:00 p.m.)
  • Alemtuzumab Reduces MS Disease Activity in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (Poster Session VII – P07.093; March 21; 2:00 p.m.)
  • Adverse Event Profile of Alemtuzumab Over Time in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE‐MS II) (Poster Session I – P01.174; March 18; 2:00 p.m.)
  • Detection, Incidence, and Management of Thyroid Autoimmunity in Comparison of Alemtuzumab and Rebif ® in Multiple Sclerosis (CARE‐MS I and II) (Poster Session I – P01.173; March 18; 2:00 p.m.)
  • Comparison of Infection Risk with Alemtuzumab and SC IFNB‐1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (Poster Session I – P01.172; March 18; 2:00 p.m.)
  • Anti-IFNB-1a Antibody Status Was Not a Factor Influencing Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (Poster Session VII – P07.125; March 21; 2:00 p.m.)
  • Immunogenicity of Alemtuzumab Treatment in Relapsing‐Remitting Multiple Sclerosis (RRMS) Patients in the CARE‐MS II Study (Poster Session VII – P07.101; March 21; 2:00 p.m.)
  • Relapse Outcomes with Alemtuzumab vs IFNB‐1a in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Experienced Disease Activity on Prior Therapy (CARE‐MS II) (Poster Session VII – P07.098; March 21; 2:00 p.m.)

Abstracts are available on the AAN website.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs